The Creso Pharma Ltd (ASX:CPH) share price is sinking on Friday after releasing an announcement. Here’s what you need to know…
The post Creso Pharma (ASX:CPH) share price sinks 9% on update appeared first on The Motley Fool Australia. –
It has been a volatile morning for the Creso Pharma Ltd (ASX: CPH) share price after returning from a trading halt.
After being up as much as 5.5% to 19 cents, the cannabis and psychedelics company’s shares are now down 9% to 16.3 cents.
Why was the Creso Pharma share price in a trading halt?
Creso Pharma requested a trading halt on Wednesday pending the release of a “material operational update” in relation to its proposed acquisition target, Halucenex Life Sciences.
This morning the company revealed that the material development that required a two-day trading halt was that Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner. Combined with its existing inventory, Halucenex Life Sciences now has total pharmaceutical grade psilocybin of 22.3 grams.
As small as this sounds, this still makes it one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. According to the release, the psilocybin will be used in research and development initiatives and future clinical trials.
Judging by the weakness in the Creso Pharma share price, investors appear underwhelmed by this announcement.
Nevertheless, Creso Pharma’s Non-Executive Chairman, Adam Blumenthal, believes it is an important development.
He commented: “Halucenex is now one of the largest holders of single batch GMP grade synthetic psilocybin in Canada. This is a major development and opens a number of doors for Halucenex in medium and long term.”
“Once it secures its licence from Health Canada, Halucenex will have the capacity to progress a number of R&D initiatives, which have the potential to unlock new drug delivery methods and combinations, potentially leading to a higher level of care through alternative treatment methods. We look forward to working with Halucenex and its existing partners to progress these research initiatives.”
“Halucenex and the Creso group more broadly continues to make steps forward. We have achieved a number of regulatory hurdles in regards to the proposed US OTC listing and anticipate DTC eligibility shortly. This will unlock considerable benefit for shareholders. We are very excited to share some of the developments the Company has been working on in the coming months,” he concluded.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why the Resolute Mining (ASX:RSG) share price is edging higher today
- Why the AVITA (ASX:AVH) share price is charging higher today
- Is the Carsales (ASX:CAR) share price in the buy zone after its acquisition?
- The Crown (ASX:CWN) share price is in focus today. Here’s why
- Is the Pro Medicus (ASX:PME) share price a buy after its contract win?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.